GET SMART NJ ABOUT ANTIBIOTIC RESISTANCE -
ACUTE bacterial sinusitis in children (16MN04-DE01)
Release Date: August 31, 2015
EXPIRED: August 31, 2016
CREDIT IS NO LONGER AVAILABLE FOR THIS ACTIVITY.
This content is being provided for informational purposes only.
Provided by Rutgers New Jersey Medical School and Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences in partnership with the New Jersey Department of Health.
This activity is supported by an educational grant from the New Jersey Department of Health. There are no fees for participating and receiving CME credit for this activity.
Antibiotic-resistant infections have become a major concern for the community and health care providers. Once a problem limited to health care facilities, there is mounting evidence that antibiotic-resistant bacteria are causing increasing proportions of serious infections in community settings.
Physician education is an important strategy for preventing and controlling antibiotic-resistant infections. We have developed this user-friendly, on-line educational activity to promote adherence to appropriate antibiotic prescribing guidelines for the treatment of upper respiratory infections in the pediatric population among physicians.
Statement of Need
Physicians commonly prescribe antibiotics for common upper respiratory infections and need to update their knowledge base, using current accepted clinical practice guidelines. This activity will improve health care provider awareness regarding antimicrobial resistance and judicious antibiotic use.
This activity is designed for primary care clinicians involved with or interested in the management of acute bacterial sinusitis in children.
Upon completion of this activity, participants should be able to:
Recognize the differences and commonalities between pediatric viral rhinosinusitis and acute bacterial sinusitis.
Describe criteria for the diagnosis of uncomplicated pediatric acute bacterial sinusitis.
Cite criteria for when antibiotics are indicated in the management of acute sinusitis in children.
List correct antibiotic choices, doses and durations for use when antibiotics are indicated in the management acute sinusitis in children.
State the elements of appropriate symptomatic relief when viral rhinosinusitis is suspected.
Identify appropriate and inappropriate scenarios for the prescription of antibiotics in cases of sinusitis.
Method of Instruction
Participants should read the activity information and review the activity in its entirety. Register for the program to access and complete the post-test and evaluation. Upon completing the activity as designed and achieving a passing score on the post-test, participants will receive a letter of credit/participation via email.
CREDIT FOR THIS ACTIVITY IS NO LONGER AVAILABLE.
Anushua Sinha, MD, MPH
Associate Professor of Preventive Medicine and Community Health
Rutgers New Jersey Medical School, Newark, NJ
Peter N. Wenger, MD
Infectious Disease Pediatrician, Division of Allergy, Immunology & Infectious Diseases, The Children’s Hospital, Saint Peter’s University Hospital, New Brunswick, NJ
Peer Review Statement
In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, CCOE has resolved all potential and real conflicts of interest through content review by non-conflicted, qualified reviewers. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by:
Edward Lifshitz, MD, FACP
Medical Director, Communicable Disease Service
New Jersey Department of Health, Trenton, NJ
Suzanne Miro, MPH, MCHES
Senior Health Communications Specialist, Communicable Disease Service
New Jersey Department of Health, Trenton, NJ
Field Test Statement
This activity was pilot-tested for time required for participation by Daniel Krich, DO and Adin Nelson, MD.
In accordance with the disclosure policies of Rutgers and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this education activity are required to disclose to the activity participants: the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device that is not yet approved.
Anushua Sinha, MD, MPH and Peter N. Wenger, MD have no relevant financial relationships to disclose.
Edward Lifshitz, MD, FACP and Suzanne Miro, MPH, MCHES have no relevant financial relationships to disclose.
Daniel Krich, DO and Adin Nelson, MD have no relevant financial relationships to disclose.
Patrick Dwyer, Director, Continuing Medical Education, has no relevant financial relationships to disclose.
Off-Label / Investigational Use Disclosure
This activity does not contain information about commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, Rutgers, or the New Jersey Department of Health.
It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products or procedures before using them in clinical practice.
Copyright © 2015 Rutgers, The State University of New Jersey. All rights reserved including translation into other languages. No part of these activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval systems, without written permission from the Rutgers.
This program is best viewed at a resolution of 1024 x 768 or higher using Microsoft Internet Explorer 6 or later.
A high-speed Internet connection, such as ISDN, T-1, DSL or Cable, is recommended.
Flash Player 6.0.79 or later (http://www.adobe.com/go/getflash) (Flash Player 7 or later recommended), and one of the following browsers:
- Windows: Internet Explorer versions 6-11, Firefox 1.x and later, Safari 3 and later, Google Chrome, Opera 9.5 and later
- Macintosh: Safari 3 and later, Firefox 1.x and later, Google Chrome
- Linux: Firefox 1.x and later
If you do not have the Adobe Flash Player, you can download this free plug-in from Adobe.com.
Please direct CE related or technical questions to Rutgers at 973-972-4267 or email email@example.com.